Bonesupport Holding AB

Historical price data

Bonesupport's mission is to revolutionize bone regeneration by overcoming the limitations of traditional bone grafts with its innovative CERAMENT® technology. The company has achieved significant milestones, including FDA approvals for CERAMENT G and V, and has transitioned into a revenue-generating commercial entity with a growing direct sales force. Its strategy focuses on expanding clinical indications, deepening market penetration in core geographies, and leveraging its platform for future product iterations to address a multi-billion dollar global market.

The CERAMENT platform is an injectable, osteoconductive, and fully resorbable bone graft substitute composed of calcium sulfate and hydroxyapatite. Its key innovation is the ability to serve as a scaffold for bone growth while optionally providing sustained, localized elution of antibiotics (gentamicin) directly at the surgical site.

Bonesupport's primary competition in infected bone cases comes from non-resorbable antibiotic-loaded PMMA beads, against which CERAMENT G holds a decisive advantage due to its resorbability and osteoconductivity. In the broader bone graft market, it competes with traditional grafts, other synthetic ceramics, and growth factor-based products, differentiating itself through its unique combination of injectability, resorption, and localized drug delivery.